A residue of the ETS domain mutated in the v-ets oncogene is essential for the DNA-binding and transactivating properties of the ETS-1 and ETS-2 proteins

Nucleic Acids Res. 1994 Sep 25;22(19):3871-9. doi: 10.1093/nar/22.19.3871.

Abstract

The c-ets-1 locus encodes two transcription factors, p54c-ets-1 and p68c-ets-1 that recognize purine-rich motifs. The v-ets oncogene of the avian retrovirus E26 differs from its cellular progenitor p68c-ets-1 by two amino acid substitutions (alanine 285 and isoleucine 445 in c-ets-1 both substituted by valine in v-ets, mutations A and B respectively) and its carboxy-terminal end (mutation C). The B mutation affects a well conserved residue in the carboxy-terminal 85 amino acids, ETS DNA-binding domain. To address the biological relevance of the B mutation found between v-ets and c-ets-1, we have randomly mutagenized isoleucine 445 of p68c-ets-1 by polymerase chain reaction. Using in vitro gel mobility shift assays, we show that this residue is crucial for the binding properties of c-ets-1 since the 12 mutations we have generated at this position, all diminish or even abolish the binding, to the 'optimized' Ets-1 binding site (EBS), of 35 kDa proteins corresponding to the 311 carboxy-terminal residues of c-ets-1. Among them, substitutions of isoleucine to glutamic acid, glycine or proline have the highest inhibitory effects. Similar results were obtained when the same mutations were introduced either in full-length p68c-ets-1 protein or into a carboxy-terminal polypeptide of 109 amino acids encompassing the ETS-domain which has previously been shown to display a very high binding activity as compared with the full-length protein. Consistent with the in vitro results, point mutations in p68c-ets-1 that decrease binding activity to EBS abrogate its ability to transactivate reporter plasmids carrying either the TPA Oncogene Response Unit of the Polyoma virus enhancer (TORU) or a sequence derived from the HTLV-1 LTR. Furthermore, as this isoleucine residue is rather well-conserved within the ETS gene family, we show that mutation of the corresponding isoleucine of c-ets-2 into glycine also abrogates its DNA-binding and hence, transactivating properties. Thus, the v-ets B mutation highlights the isoleucine 445 as an essential amino acid of the c-ets-1 and c-ets-2 DNA-binding domains.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3 Cells
  • Amino Acid Sequence
  • Animals
  • Base Sequence
  • Binding Sites
  • Conserved Sequence
  • DNA / chemistry
  • DNA / metabolism*
  • DNA-Binding Proteins*
  • Escherichia coli / genetics
  • Isoleucine / genetics
  • Mice
  • Molecular Sequence Data
  • Mutagenesis, Site-Directed*
  • Proto-Oncogene Protein c-ets-1
  • Proto-Oncogene Protein c-ets-2
  • Proto-Oncogene Proteins / chemistry
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins / physiology*
  • Proto-Oncogene Proteins c-ets
  • Repressor Proteins*
  • Retroviridae Proteins, Oncogenic / chemistry
  • Retroviridae Proteins, Oncogenic / genetics*
  • Structure-Activity Relationship
  • Trans-Activators*
  • Transcription Factors*
  • Transcriptional Activation*
  • Transfection

Substances

  • DNA-Binding Proteins
  • ERF protein, human
  • ETS1 protein, human
  • Ets1 protein, mouse
  • Ets2 protein, mouse
  • Proto-Oncogene Protein c-ets-1
  • Proto-Oncogene Protein c-ets-2
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-ets
  • Repressor Proteins
  • Retroviridae Proteins, Oncogenic
  • Trans-Activators
  • Transcription Factors
  • oncogene proteins v-ets
  • Isoleucine
  • DNA